Drug Target Review

JULY 25, 2023

The workflow, which has been termed STING-seq, integrates biobank-scale GWAS data with CRISPR and single-cell sequencing techniques, allowing for the identification of target genes associated with noncoding variants for blood traits. Dr Sanjana elaborated on the study for Drug Target Review. This is a great question. Yet some people do not.

Cell Based Assays 98

Cell Based Assays Disease Therapies Science 98

Broad Institute

JUNE 30, 2023

Typically, studying drug therapies is an expensive and time-consuming undertaking. With high-resolution, cell-based profiling techniques, extracting a large amount of data can be done cheaply and efficiently.

Small Molecule 105

Small Molecule Cell Based Assays Disease Assay Development 105

Alta Sciences

OCTOBER 31, 2023

All three laboratories across North America are uniformly designed and managed. Whether as a standalone bioanalytical service or as part of an integrated program, Altasciences provides top-quality data for TK, PK, and PD determinations to support preclinical and clinical studies.

Laboratories 52

Laboratories Clinical Pharmacology Cell Based Assays Drug Development 52

Broad Institute

JUNE 21, 2023

The researchers also looked at the tool’s ability to detect changes in cell morphology after exposure to drugs and small molecule compounds. Typically, studying drug therapies is an expensive and time-consuming undertaking.

Small Molecule 52

Small Molecule Cell Based Assays Medical Schools Disease 52

Molecular Design

JUNE 8, 2023

Taking into account changes in their physicochemical properties over time, drugs are analyzed according to their target class, therapy area, and route of administration. Using ChEMBL version 26, a data set of 643 drugs acting on 271 targets was assembled, comprising 1104 drug−target pairs having ≥100 published compounds per target.

Cell Based Assays 62

Cell Based Assays Small Molecule Drugs Marketing 62

The Pharma Data

OCTOBER 15, 2020

ASLAN003 is a highly selective and potent inhibitor of human DHODH (IC 50 = 35 nM) and has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme in cell free and cell-based assays than the first generation inhibitor teriflunomide. For additional information please visit www.aslanpharma.com.

Pharmaceuticals 40

Pharmaceuticals Cell Based Assays Clinical Development Treatment 40

Agency IQ

APRIL 12, 2024

Draft guidance on potency assays for CGT products garners extensive stakeholder input Late last year, the FDA published a draft update to its 2011 guidance on potency assays for cell and gene therapy products, unveiling a major shift in approach to the issue.

Production 40

Production FDA Therapies Biochemical Assays 40